Sofia Bonomelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sofia Bonomelli has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Padovani
Department of clinical and experimental sciences University of Brescia Brescia Italy
1 shared publication - Alice Galli
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy
1 shared publication - Andrea Pilotto
Department of clinical and experimental sciences University of Brescia Brescia Italy
1 shared publication - Andrea Rizzardi
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy
1 shared publication - Cinzia Zatti
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy
1 shared publication - Clint Hansen
Department of Neurology, University Hospital Schleswig-Holstein and Kiel University, Kiel, Germany
1 shared publication
Latest Publications
- Open Access
Wearable Inertial Sensor Analysis of Turning Performance Reveals Motor Reserve Effects in Drug-Naïve Parkinson’s Disease
Introduction: Motor reserve (MR) has been hypothesized as a protective factor against age-related and pathological motor decline, potentially enhancing quality of life. This study aimed to investigate the influence of MR on motor performance, assessed via mobile health technology (MHT), in drug-naïve Parkinson’s disease (PD) patients. Methods: Consecutive drug-naïve PD patients and age-matched healthy controls (HC) underwent cognitive and motor assessments. Turning MHT parameters were extracted from the Timed Up and Go test (TUG) performed at self-selected and fast speeds. Participants were categorized into high- or low-MR groups based on the Motor Reserve Index questionnaire (MRIq). Results: Forty-five PD patients and forty healthy controls (HC) were enrolled. PD patients showed longer TUG durations and altered performance compared to HC. No differences were found between high and low motor reserve (MR) groups in demographics or clinical severity. However, high-MR patients exhibited shorter turn duration and higher angular velocities at both self-selected (p < 0.005) and fast speeds (p < 0.05). MR subdomains related to physical and care activities correlated with MHT turning metrics, unlike housework and leisure domains. Conclusions: the findings highlighted the relevance of MR on motor performances assessed by MHT in drug naïve PD, independently from motor severity.
Open AccessWearable Inertial Sensor Analysis of Turning Performance Reveals Motor Reserve Effects in Drug-Naïve Parkinson’s Disease
Introduction: Motor reserve (MR) has been hypothesized as a protective factor against age-related and pathological motor decline, potentially enhancing quality of life. This study aimed to investigate the influence of MR on motor performance, assessed via mobile health technology (MHT), in drug-naïve Parkinson’s disease (PD) patients. Methods: Consecutive drug-naïve PD patients and age-matched healthy controls (HC) underwent cognitive and motor assessments. Turning MHT parameters were extracted from the Timed Up and Go test (TUG) performed at self-selected and fast speeds. Participants were categorized into high- or low-MR groups based on the Motor Reserve Index questionnaire (MRIq). Results: Forty-five PD patients and forty healthy controls (HC) were enrolled. PD patients showed longer TUG durations and altered performance compared to HC. No differences were found between high and low motor reserve (MR) groups in demographics or clinical severity. However, high-MR patients exhibited shorter turn duration and higher angular velocities at both self-selected (p < 0.005) and fast speeds (p < 0.05). MR subdomains related to physical and care activities correlated with MHT turning metrics, unlike housework and leisure domains. Conclusions: the findings highlighted the relevance of MR on motor performances assessed by MHT in drug naïve PD, independently from motor severity.